Company Overview and News

 
These 10 stocks were hammered in 2018, do you own any?

2018-10-09 moneycontrol
Since the turn of the year, the Indian benchmark indices have not witnessed significant erosion in value, but large cap stocks have been hit badly. Here are some of the worst performing stocks of the year, to date. The list has been compiled by Moneycontrol by sifting through the Ace Equity database. The comparative analysis undertaken here includes only the stocks of companies with market capitalisation above Rs 5,000 crore.
SUZLON SRI SREINFRA JIPKY 532617 532712 RCOM 532461 SUEL YESBANK SIFLY 523756 532627 JETAIRWAYS JPASSOCIAT 532648 SRIA YYBKY 532667 532532 PNJZY JPPOWER PNB 534809 PCJEWELLER

 
ICICI Bank moves NCLT against Jaiprakash Power

2018-10-04 financialexpress
ICICI Bank has initiated insolvency proceedings against Jaiprakash Power Ventures, filing an application under Section 7 of the Insolvency and Bankruptcy Code (IBC) with the Ahmedabad bench of the National Company Law Tribunal (NCLT). The company’s total debt stood at Rs 20,143 crore at the end of March 2018. In a notice to the exchanges, Jaiprakash Power said on Thursday, “This is to inform you that as per the notice received by the Company, ICICI Bank has filed an application under Section 7 of the Insolvency and Bankruptcy Code, 2016, for initiating Corporate Insolvency Resolution Process (CIRP) for the company with the National Company Law Tribunal (NCLT), Ahmedabad.
532532 ICICIBANK JIPKY 532174 IBN 532627 JPPOWER JPASSOCIAT

 
DHFL, YES Bank, Infibeam, ILFS Transport top losers among BSE Group A stocks

2018-09-21 moneycontrol
Indian stock market staged some recovery in the afternoon session with the Nifty down 91 points and closing at 11,143 while the Sensex falling 280 points and ending the day at 36,841 mark.
GPTINFRA YESBANK THIRUSUGAR 511072 JIPKY JPASSOCIAT 532648 YYBKY 533761 532832 532532 DHFL 507450 IBREALEST

 
Independent director of Jaypee Infratech ‘Sham Lal Mohan’ resigns

2018-09-17 freepressjournal.in
New Delhi: Jaypee Infratech, which is facing insolvency proceedings, Monday said that the company’s independent director Sham Lal Mohan has resigned citing personal reasons. Last week, three independent directors Lalit Bhasin, Keshav Prasad Rau and Basant Kumar Goswami had resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
Another independent director of Jaypee Infratech resigns; fourth in last one week

2018-09-17 moneycontrol
Jaypee Infratech, which is facing insolvency proceedings, Monday said that the company's independent director Sham Lal Mohan has resigned citing personal reasons. Last week, three independent directors Lalit Bhasin, Keshav Prasad Rau and Basant Kumar Goswami had resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

 
One more independent director of Jaypee Infratech resigns

2018-09-12 moneycontrol
Debt-ridden Jaypee Infratech, which is facing insolvency proceedings,said that its independent director Lalit Bhasin has resigned from the board.
UBNC AXB JIPKY IBN JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...